Virtus ETF Advisers LLC Purchases 1,132 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Virtus ETF Advisers LLC grew its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 38.8% in the 4th quarter, Holdings Channel reports. The firm owned 4,051 shares of the biotechnology company’s stock after acquiring an additional 1,132 shares during the quarter. Virtus ETF Advisers LLC’s holdings in Arcturus Therapeutics were worth $69,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. KLP Kapitalforvaltning AS acquired a new stake in shares of Arcturus Therapeutics during the 4th quarter worth approximately $71,000. National Bank of Canada FI grew its position in shares of Arcturus Therapeutics by 639.6% during the 4th quarter. National Bank of Canada FI now owns 5,532 shares of the biotechnology company’s stock worth $94,000 after buying an additional 4,784 shares during the period. Kennedy Capital Management LLC grew its position in shares of Arcturus Therapeutics by 22.7% during the 4th quarter. Kennedy Capital Management LLC now owns 10,987 shares of the biotechnology company’s stock worth $186,000 after buying an additional 2,036 shares during the period. SG Americas Securities LLC grew its position in shares of Arcturus Therapeutics by 45.0% during the 4th quarter. SG Americas Securities LLC now owns 11,940 shares of the biotechnology company’s stock worth $203,000 after buying an additional 3,705 shares during the period. Finally, Spire Wealth Management grew its position in shares of Arcturus Therapeutics by 393.3% during the 4th quarter. Spire Wealth Management now owns 13,478 shares of the biotechnology company’s stock worth $229,000 after buying an additional 10,746 shares during the period. Institutional investors and hedge funds own 94.54% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of Arcturus Therapeutics in a research report on Thursday, April 10th. Wells Fargo & Company reduced their price target on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating for the company in a research report on Friday, March 7th. BTIG Research set a $48.00 price target on shares of Arcturus Therapeutics and gave the company a “buy” rating in a research report on Monday, March 10th. Canaccord Genuity Group reduced their price target on shares of Arcturus Therapeutics from $74.00 to $68.00 and set a “buy” rating for the company in a research report on Monday, March 10th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a research report on Friday, March 7th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $59.20.

Arcturus Therapeutics Price Performance

ARCT opened at $12.82 on Tuesday. The company has a market capitalization of $347.68 million, a price-to-earnings ratio of -5.77 and a beta of 3.41. The firm’s fifty day moving average price is $12.68 and its two-hundred day moving average price is $15.96. Arcturus Therapeutics Holdings Inc. has a 1 year low of $8.04 and a 1 year high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.78). The firm had revenue of $22.77 million for the quarter, compared to analysts’ expectations of $44.64 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. As a group, equities analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.22 EPS for the current year.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.